Immunic Advances MS Pipeline as Phase 3 Enrollment Completed
Event summary
- Immunic completed enrollment in both Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis (RMS), expecting top-line data by end-2026.
- Phase 2 CALLIPER data demonstrated a reduction in 24-week confirmed disability worsening (24wCDW) and improvement (24wCDI) across progressive multiple sclerosis (PMS) subtypes.
- Long-term data from the Phase 2 EMPhASIS trial showed 92.3% of patients remained free of confirmed disability worsening at week 144.
- Immunic secured a U.S. patent allowance for vidofludimus calcium dose strengths in PMS, extending intellectual property protection to 2041.
The big picture
Immunic's progress on vidofludimus calcium represents a potential shift in the treatment paradigm for multiple sclerosis, targeting neurodegeneration—a critical unmet need—rather than solely focusing on inflammation. The company's dual mechanism of action and favorable safety profile could position vidofludimus calcium as a differentiated option, but success depends on robust Phase 3 data. The company's broader pipeline, including IMU-856, offers diversification but requires further development and potential partnerships to reach its full potential.
What we're watching
- Clinical Outcomes
- The success of the ENSURE trials will hinge on demonstrating statistically significant and clinically meaningful efficacy in RMS, given the existing treatment landscape.
- Regulatory Pathway
- The FDA's acceptance of 24wCDW as a PMS endpoint could expedite regulatory review, but Immunic must demonstrate consistency across diverse patient populations.
- Pipeline Diversification
- The progress of IMU-856 in gastrointestinal disorders and potential weight management will be crucial to Immunic’s long-term growth beyond its MS franchise.
Related topics